Related Experiment Video
Updated: May 25, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.6K
Left Atrial Appendage Occlusion: British Cardiovascular Intervention Society and British Heart Rhythm Society
Tim R Betts1, Patrick A Calvert2, Lee N Graham3
1Cardiac Electrophysiology, Oxford University Hospitals NHS Foundation Trust Oxford, UK.
Arrhythmia & Electrophysiology Review
|March 28, 2024
Summary
Percutaneous left atrial appendage occlusion offers a stroke risk reduction strategy for atrial fibrillation patients unsuitable for anticoagulation. This statement details evidence, indications, and best practices for the procedure.
Area of Science:
- Cardiology
- Medical Devices
- Interventional Procedures
Background:
- Atrial fibrillation (AF) poses a significant stroke risk, especially in patients contraindicated for anticoagulation.
- Percutaneous left atrial appendage (LAA) occlusion is an alternative strategy to reduce thromboembolic events.
- The procedure has gained regulatory approval and is supported by international trial data.
Purpose of the Study:
- To summarize the evidence supporting LAA occlusion.
- To outline current clinical indications for LAA occlusion.
- To provide consensus on best practices for LAA occlusion procedures.
Main Methods:
- Review of international randomized trials and registries.
- Analysis of National Institute for Health and Care Excellence (NICE) and NHS England guidelines.
- Consensus-based recommendations for procedural planning, execution, and follow-up.
Main Results:
- LAA occlusion is an established procedure for stroke risk reduction in select AF patients.
- Evidence supports its use, particularly for those who cannot tolerate anticoagulation.
- Guidelines exist for its safe and effective implementation.
Conclusions:
- LAA occlusion is a viable option for stroke prevention in specific atrial fibrillation populations.
- Standardized approaches to pre-procedure planning, implantation, and post-procedure care are essential.
- Establishing procedural volume standards and multidisciplinary team involvement is recommended for optimal outcomes.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...